Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.

Kiener M, Chen L, Krebs M, Grosjean J, Klima I, Kalogirou C, Riedmiller H, Kneitz B, Thalmann GN, Snaar-Jagalska E, Spahn M, Kruithof-de Julio M, Zoni E.

BMC Cancer. 2019 Jun 25;19(1):627. doi: 10.1186/s12885-019-5819-6.

2.

A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer.

Ventimiglia E, Seisen T, Abdollah F, Briganti A, Fonteyne V, James N, Roach M 3rd, Thalmann GN, Touijer K, Chen RC, Cheng L.

Eur Urol Oncol. 2019 May;2(3):294-301. doi: 10.1016/j.euo.2019.02.001. Epub 2019 Mar 23. Review.

PMID:
31200844
3.

Identification of ureteral stones at reduced radiation exposure: a pilot study comparing conventional versus digital low-dosage linear slot scanning (Lodox®) radiography.

Fiechter S, Geissbühler E, Bähler A, Obmann V, Meierhans S, Exadaktylos AK, Christe A, Thalmann GN, Roth B.

World J Urol. 2019 Jun 5. doi: 10.1007/s00345-019-02803-w. [Epub ahead of print]

PMID:
31165230
4.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ.

Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14.

5.

Lessons Learned by Pushing the Limits?

Thalmann GN, Wuethrich PY, Burkhard FC.

Eur Urol Oncol. 2018 Sep;1(4):305-306. doi: 10.1016/j.euo.2018.08.006. Epub 2018 Sep 6. No abstract available.

PMID:
31100251
6.

Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy.

Shelan M, Odermatt S, Bojaxhiu B, Nguyen DP, Thalmann GN, Aebersold DM, Dal Pra A.

Front Oncol. 2019 Feb 28;9:12. doi: 10.3389/fonc.2019.00012. eCollection 2019.

7.

Therapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer.

Zoni E, Astrologo L, Ng CKY, Piscuoglio S, Melsen J, Grosjean J, Klima I, Chen L, Snaar-Jagalska EB, Flanagan K, van der Pluijm G, Kloen P, Cecchini MG, Kruithof-de Julio M, Thalmann GN.

Mol Cancer Res. 2019 May;17(5):1049-1062. doi: 10.1158/1541-7786.MCR-18-1220. Epub 2019 Feb 11.

PMID:
30745464
8.

Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution.

Roth B, Furrer MA, Giannakis I, Vartolomei MD, Boxler S, Wuethrich PY, Burkhard FC, Thalmann GN, Kiss B.

J Urol. 2019 May;201(5):909-915. doi: 10.1097/JU.0000000000000034.

PMID:
30694935
9.

[Instillation therapies for urothelial carcinoma of the upper urinary tract].

Bosshard P, Thalmann GN, Roth B.

Urologe A. 2019 Jan;58(1):25-29. doi: 10.1007/s00120-018-0830-0. Review. German.

PMID:
30649582
10.

The Comprehensive Complication Index CCI: A proposed modification to optimize short-term complication reporting after cystectomy and urinary diversion.

Furrer MA, Huesler J, Fellmann A, Burkhard FC, Thalmann GN, Wuethrich PY.

Urol Oncol. 2019 Apr;37(4):291.e9-291.e18. doi: 10.1016/j.urolonc.2018.12.013. Epub 2019 Jan 9.

PMID:
30638668
11.

No survival benefit with extended lymphadenectomy: now what?

Burkhard FC, Thalmann GN.

Nat Rev Urol. 2019 Jan;16(1):3-4. doi: 10.1038/s41585-018-0126-6. No abstract available.

PMID:
30510274
12.

Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.

Rentsch CA, Derré L, Dugas SG, Wetterauer C, Federer-Gsponer JR, Thalmann GN, Ingersoll MA.

Eur Urol Focus. 2018 Jul;4(4):485-493. doi: 10.1016/j.euf.2018.10.010. Epub 2018 Nov 8. Review.

PMID:
30415921
13.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.

Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.

14.

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.

Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6.

15.

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2019 Aug 15;25(16):5082-5093. doi: 10.1158/1078-0432.CCR-18-1106. Epub 2018 Sep 17.

PMID:
30224344
16.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.

PMID:
30073676
17.

Osteolytic cancer cells induce vascular/axon guidance processes in the bone/bone marrow stroma.

Hensel J, Wetterwald A, Temanni R, Keller I, Riether C, van der Pluijm G, Cecchini MG, Thalmann GN.

Oncotarget. 2018 Jun 22;9(48):28877-28896. doi: 10.18632/oncotarget.25608. eCollection 2018 Jun 22.

18.

Robot-assisted versus open cystectomy.

Seiler R, Thalmann GN.

Lancet. 2018 Jun 23;391(10139):2479-2480. doi: 10.1016/S0140-6736(18)31309-6. No abstract available.

PMID:
29976454
19.

Erratum: Metastases in Prostate Cancer.

La Manna F, Karkampouna S, Zoni E, De Menna M, Hensel J, Thalmann GN, Kruithof-de Julio M.

Cold Spring Harb Perspect Med. 2018 Jul 2;8(7). pii: a035568. doi: 10.1101/cshperspect.a035568. No abstract available.

20.

Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients?

Thoeny HC, Bellin MF, Comperat EM, Thalmann GN.

Eur Urol. 2018 Sep;74(3):307-308. doi: 10.1016/j.eururo.2018.06.017. Epub 2018 Jun 28. No abstract available.

PMID:
29960749
21.

Metastases in Prostate Cancer.

Manna F, Karkampouna S, Zoni E, De Menna M, Hensel J, Thalmann GN, Kruithof-de Julio M.

Cold Spring Harb Perspect Med. 2019 Mar 1;9(3). pii: a033688. doi: 10.1101/cshperspect.a033688. Review. Erratum in: Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):.

PMID:
29661810
22.

CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.

Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.

J Pathol. 2018 Jul;245(3):297-310. doi: 10.1002/path.5083. Epub 2018 May 9.

PMID:
29604056
23.

The anatomy of the male inferior hypogastric plexus: What should we know for nerve sparing surgery.

Röthlisberger R, Aurore V, Boemke S, Bangerter H, Bergmann M, Thalmann GN, Djonov V.

Clin Anat. 2018 Sep;31(6):788-796. doi: 10.1002/ca.23079. Epub 2018 Oct 24.

24.

Repeat prostate biopsies prior to radical prostatectomy do not impact erectile function recovery and mid- to long-term continence.

Furrer MA, Vilaseca A, Corradi RB, Boxler S, Thalmann GN, Nguyen DP.

Prostate. 2018 Jun;78(8):631-636. doi: 10.1002/pros.23509. Epub 2018 Mar 14.

PMID:
29542169
25.

Reproductive organ-sparing cystectomy significantly improves continence in women after orthotopic bladder substitution without affecting oncological outcome.

Gross T, Furrer M, Schorno P, Wuethrich PY, Schneider MP, Thalmann GN, Burkhard FC.

BJU Int. 2018 Aug;122(2):227-235. doi: 10.1111/bju.14191. Epub 2018 Apr 2.

26.

An Accurate Diagnostic Pathway Helps to Correctly Distinguish Between the Possible Causes of Acute Scrotum.

Roth B, Giannakis I, Ricklin ME, Thalmann GN, Exadaktylos AK.

Oman Med J. 2018 Jan;33(1):55-60. doi: 10.5001/omj.2018.10.

27.

Nerve-sparing radical cystectomy has a beneficial impact on urinary continence after orthotopic bladder substitution, which becomes even more apparent over time.

Furrer MA, Studer UE, Gross T, Burkhard FC, Thalmann GN, Nguyen DP.

BJU Int. 2018 Jun;121(6):935-944. doi: 10.1111/bju.14123. Epub 2018 Feb 4.

28.

ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models.

Astrologo L, Zoni E, Karkampouna S, Gray PC, Klima I, Grosjean J, Goumans MJ, Hawinkels LJAC, van der Pluijm G, Spahn M, Thalmann GN, Ten Dijke P, Kruithof-de Julio M.

Front Cell Dev Biol. 2017 Dec 5;5:104. doi: 10.3389/fcell.2017.00104. eCollection 2017.

29.

Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10.

Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Stein J, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Dal Pra A, Biaggi Rudolf C, Wust P, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2018 Feb;126(2):257-262. doi: 10.1016/j.radonc.2017.10.025. Epub 2017 Nov 3.

PMID:
29103826
30.

The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma.

Gakis G, Schubert T, Morgan TM, Daneshmand S, Keegan KA, Mischinger J, Clayman RH, Brisuda A, Ali-El-Dein B, Galland S, Gregg J, Balci M, Olugbade K Jr, Rink M, Fritsche HM, Burger M, Babjuk M, Stenzl A, Thalmann GN, Kübler H, Efstathiou JA.

Urol Oncol. 2018 Jan;36(1):10.e7-10.e14. doi: 10.1016/j.urolonc.2017.09.012. Epub 2017 Oct 18.

PMID:
29055518
31.

Impact of Packed Red Blood Cells and Fresh Frozen Plasma Given During Radical Cystectomy and Urinary Diversion on Cancer-related Outcome and Survival: An Observational Cohort Study.

Furrer MA, Fellmann A, Schneider MP, Thalmann GN, Burkhard FC, Wuethrich PY.

Eur Urol Focus. 2018 Dec;4(6):916-923. doi: 10.1016/j.euf.2017.09.010. Epub 2017 Sep 23.

PMID:
28951117
32.

More extended lymph node dissection template at radical prostatectomy detects metastases in the common iliac region and in the fossa of Marcille.

Maderthaner L, Furrer MA, Studer UE, Burkhard FC, Thalmann GN, Nguyen DP.

BJU Int. 2018 May;121(5):725-731. doi: 10.1111/bju.13993. Epub 2017 Sep 17.

33.

Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.

Genitsch V, Zlobec I, Seiler R, Thalmann GN, Fleischmann A.

Int J Mol Sci. 2017 Jul 28;18(8). pii: E1640. doi: 10.3390/ijms18081640.

34.

Therapy-related longitudinal brain perfusion changes in patients with chronic pelvic pain syndrome.

Weisstanner C, Mordasini L, Thalmann GN, Verma RK, Rummel C, Federspiel A, Kessler TM, Wiest R.

Swiss Med Wkly. 2017 Aug 2;147:w14454. doi: 10.4414/smw.2017.14454. eCollection 2017.

35.

Sentinel nodes in prostate cancer- are we chasing a ghost?

Thalmann GN, Nguyen DP.

BJU Int. 2017 Aug;120(2):161-162. doi: 10.1111/bju.13895. No abstract available.

36.

Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence.

Kiss B, Furrer MA, Wuethrich PY, Burkhard FC, Thalmann GN, Roth B.

J Urol. 2017 Dec;198(6):1263-1268. doi: 10.1016/j.juro.2017.06.020. Epub 2017 Jun 8.

PMID:
28603003
37.

An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.

Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Ørum-Madsen MS, Agerbæk MØ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenhöfer T, Esfandnia S, Battsogt D, Babcook JS, Al-Nakouzi N, Crabb SJ, Moskalev I, Kiss B, Davicioni E, Thalmann GN, Rennie PS, Black PC, Salanti A, Daugaard M.

Eur Urol. 2017 Jul;72(1):142-150. doi: 10.1016/j.eururo.2017.03.021. Epub 2017 Apr 10.

PMID:
28408175
38.

[Therapeutic management of blunt testicular trauma].

Lyttwin B, Moltzahn F, Thalmann GN.

Urologe A. 2017 Jul;56(7):864-867. doi: 10.1007/s00120-017-0383-7. Review. German.

PMID:
28405707
39.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
40.

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, Attard G, Cross W, Jones RJ, Parker CC, Russell JM, Thalmann GN, Schiavone F, Cassoly E, Matheson D, Millman R, Rentsch CA, Barber J, Gilson C, Ibrahim A, Logue J, Lydon A, Nikapota AD, O'Sullivan JM, Porfiri E, Protheroe A, Srihari NN, Tsang D, Wagstaff J, Wallace J, Walmsley C, Parmar MKB, Sydes MR; STAMPEDE Investigators.

J Clin Oncol. 2017 May 10;35(14):1530-1541. doi: 10.1200/JCO.2016.69.0677. Epub 2017 Mar 13.

41.

Contemporary update on neoadjuvant therapy for bladder cancer.

Nguyen DP, Thalmann GN.

Nat Rev Urol. 2017 Jun;14(6):348-358. doi: 10.1038/nrurol.2017.30. Epub 2017 Mar 14. Review.

PMID:
28290459
42.

Resetting of renal tissular renin-angiotensin and bradykinin-kallikrein systems after unilateral kidney denervation in rats.

Bohlender JM, Nussberger J, Birkhäuser F, Grouzmann E, Thalmann GN, Imboden H.

Histochem Cell Biol. 2017 May;147(5):585-593. doi: 10.1007/s00418-017-1543-y. Epub 2017 Feb 20.

PMID:
28220244
43.

Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.

Kiss B, Wyatt AW, Douglas J, Skuginna V, Mo F, Anderson S, Rotzer D, Fleischmann A, Genitsch V, Hayashi T, Neuenschwander M, Buerki C, Davicioni E, Collins C, Thalmann GN, Black PC, Seiler R.

Sci Rep. 2017 Feb 16;7:42713. doi: 10.1038/srep42713.

44.

Emerging aspects of microRNA interaction with TMPRSS2-ERG and endocrine therapy.

Zoni E, Karkampouna S, Thalmann GN, Kruithof-de Julio M, Spahn M.

Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):9-16. doi: 10.1016/j.mce.2017.02.009. Epub 2017 Feb 9. Review.

45.

Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?

Ghadjar P, Hayoz S, Zwahlen DR, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

J Clin Oncol. 2017 May 1;35(13):1490-1491. doi: 10.1200/JCO.2016.70.7265. Epub 2017 Jan 30. No abstract available.

PMID:
28135138
46.

In Regard to Pisansky et al.

Ghadjar P, Hayoz S, Zwahlen DR, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):438-439. doi: 10.1016/j.ijrobp.2016.10.019. No abstract available.

PMID:
28068252
47.

Quality improvement in cystectomy care with enhanced recovery (QUICCER) study.

Thalmann GN.

BJU Int. 2017 Jan;119(1):4-5. doi: 10.1111/bju.13553. No abstract available.

48.

Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.

Ghadjar P, Hayoz S, Genitsch V, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Khanfir K, Budach V, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK).

BJU Int. 2017 Nov;120(5B):E45-E51. doi: 10.1111/bju.13742. Epub 2017 Jan 19.

49.

MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression.

Dallavalle C, Albino D, Civenni G, Merulla J, Ostano P, Mello-Grand M, Rossi S, Losa M, D'Ambrosio G, Sessa F, Thalmann GN, Garcia-Escudero R, Zitella A, Chiorino G, Catapano CV, Carbone GM.

J Clin Invest. 2016 Dec 1;126(12):4585-4602. doi: 10.1172/JCI86505. Epub 2016 Nov 7.

50.

Oncological and functional outcomes of postoperative total parenteral nutrition after radical cystectomy in bladder cancer patients: A single-center randomized trial.

Vidal A, Arnold N, Vartolomei MD, Kiss B, Burkhard F, Thalmann GN, Roth B.

Int J Urol. 2016 Dec;23(12):992-999. doi: 10.1111/iju.13228. Epub 2016 Oct 21.

Supplemental Content

Loading ...
Support Center